4. juuli 2007

Tähelepanu! Artikkel on enam kui 5 aastat vana ning kuulub väljaande digitaalsesse arhiivi. Väljaanne ei uuenda ega kaasajasta arhiveeritud sisu, mistõttu võib olla vajalik kaasaegsete allikatega tutvumine.

<br />- PREZISTA/ritonavir data published in The Lancet - CORK- Ireland-July 5 /PRNewswire/ -- Results from a Phase 3 head-to-head studyshowed that a significantly greater percent (77 percent) oftreatment-experienced HIV-1 infected adults* taking Prezista(R)(darunavir)/ritonavir- with an optimised background regimen (OBR)of antiretroviral agents- reached a viral load of less than 400copies/mL at week 48- compared to 68 percent of patients taking thewidely prescribed medication lopinavir/ritonavir- with OBR- in aper-protocol analysis (95 percent confidence interval 2-16). Inaddition- significantly more patients receiving darunavir/r in thisstudy reached an undetectable viral load ( lt;50 copies/mL)compared to patients taking lopinavir/r (71 percent vs. 60percent).

The 48-week efficacy and safety results- published in the 7 July2007 issue of The Lancet- will also be presented at the 4thInternational AIDS Society Conference on HIV Pathogenesis-Treatment and Prevention (IAS 2007) in Sydney- Australia on 24 July2007. The study met both the primary and secondary objective ofnon-inferiority and superiority. The primary objective was todemonstrate non-inferiority in virologic response withdarunavir/ritonavir versus lopinavir/ritonavir- both combined withan individualised OBR- at week 48. If non-inferiority wasestablished- the secondary objective was to demonstrate superiorityin virologic response with darunavir/ritonavir versuslopinavir/ritonavir at week 48. Virologic response was defined as aconfirmed plasma viral load of lt;400 copies/mL.